Baillie Gifford & Co. Lowers Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Baillie Gifford & Co. decreased its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 1.5% in the fourth quarter, Holdings Channel reports. The firm owned 24,864,058 shares of the company’s stock after selling 375,812 shares during the period. Baillie Gifford & Co. owned 0.06% of Recursion Pharmaceuticals worth $168,081,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of RXRX. ARK Investment Management LLC boosted its holdings in shares of Recursion Pharmaceuticals by 16.4% in the third quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company’s stock valued at $215,949,000 after purchasing an additional 4,626,268 shares during the period. State Street Corp boosted its holdings in shares of Recursion Pharmaceuticals by 47.1% in the third quarter. State Street Corp now owns 12,870,272 shares of the company’s stock valued at $84,815,000 after purchasing an additional 4,120,685 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Recursion Pharmaceuticals by 13.7% in the third quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock valued at $35,803,000 after purchasing an additional 656,003 shares during the period. Institute for Wealth Management LLC. purchased a new stake in Recursion Pharmaceuticals during the fourth quarter worth $3,928,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Recursion Pharmaceuticals by 17.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,940,680 shares of the company’s stock worth $12,789,000 after buying an additional 288,926 shares during the period. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th. KeyCorp lowered their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th.

Recursion Pharmaceuticals Price Performance

Shares of RXRX stock opened at $10.53 on Monday. The business’s fifty day simple moving average is $7.27 and its 200-day simple moving average is $6.90. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 12-month low of $5.60 and a 12-month high of $15.74.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.